Sector News

NPS Pharma asks Goldman Sachs to find a buyer: WSJ

January 6, 2015
Life sciences
Long cited as a takeover target, rare disease specialist NPS Pharmaceuticals is seeking a buyer, according to a report in the Wall Street Journal.
 
The newspaper reports that Goldman Sachs has started to contact companies to gauge their interest in NPS, which may be available at upwards of $4.5 billion. Shire has regularly been mentioned as a potential purchaser and is on the look-out for acquisitions having had its warchest boosted by a $1.6 billion break-up fee banked after AbbVie pulled out of a proposed merger last year.
 
NPS currently markets Gattex/Revestive (teduglutide) for short bowel syndrome. It is also waiting to hear from the US Food and Administration about Natpara (recombinant human parathyroid hormone) for the treatment of hypoparathyroidism and a decision is expected by the end of this month.
 
By Kevin Grogan
 
Source: Pharma Times
 

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach